US: DSM TAKES OVER CATALYTICA PHARMACEUTICALS
Article Abstract:
By taking over the pharmaceuticals division of Catalytica in the US, DSM of Heerlen, Netherlands, expands its range of activity and is now able to offer the full range of pharmaceutical services and products from the development of active agents to finished products. DSM is paying US$ 800mn for Catalytica, which generated a turnover of US$ 423.7mn in 1999. Earnings before interest and taxes amounted to US$ 51mn and net profit US$ 27mn. R&D contracts contributed US$ 25.6mn to turnover. The takeover raises the annual turnover of DSM's fine chemicals division to EUR 2.2bn, of which the pharmaceutical industry accounts for EUR 1.4bn. This makes DSM the market leader ahead of Clariant, Lonza, Rhodia, Bayer and Degussa-Huls. Between them DSM and Catalytica have development contracts for 85 intermediaries and active agents. They should generate additional earnings of more than US$ 220mn in year 2003. Catalytica has production plants in Greenville, New Carolina; South Haven, Michigan; and Bay View, California. The non-pharmaceutical operations of Catalytica, i.e. catalysts and incineration facilities, are to be hived off.
Publication Name: Chemische Rundschau
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0009-2983
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
NETHERLANDS/US: DSM AND MEGABIOS COOPERATE
Article Abstract:
Dutch DSM Biologics and US Megabios Corporation of Burlingame, California, agreed on a cooperation concerning the production of plasmid DNA and lipid DNA complexes. DSM will receive a licence for the production procedure developed by Megabios. DSM will use the procedure in its Canadian plant in Montreal. Also, it can be applied in the Dutch plant in Groningen. On the other hand, Megabios will be paid licence and contingent fees. The profit will be shared. The companies regard the market potential for therapeutics based on plasmids to be significant. Production of plasmid DNA and lipid DNA complexes is to start in 2001. Up to then, the pharmaceutical sector will be supplied with development products.
Publication Name: Chemische Rundschau
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0009-2983
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
AUSTRIA: AMERICAN HOME PRODUCTS IN EAST EUROPE
Article Abstract:
American Home Products of the US expects to generate a turnover of US$ 70mn in eastern Europe through Wyeth-Whitehall Export GmbH in year 2000. The new Vienna-based company expects sales in central and eastern Europe, including Russia and the Commonwealth of Independent States, to grow at an annual rate of 25% to 30% in US dollar terms.
Publication Name: Chemische Rundschau
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0009-2983
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: SWITZERLAND/UK: ARES SERONO, BRITISH BIOTECH R&D. AUSTRIA: SANOCHEMIA BOOSTS SYNTHESIS. SWEDEN: REMYNIL BY SANOCHEMIA
- Abstracts: GERMANY/US: CANCER R&D DEAL BY COLEY, LUDWIG. US: ROCHE INVESTS IN CANCER RESEARCH. US: MITOTIX BOUGHT BY GERMAN GPC
- Abstracts: US: KNOLL TO PAY DAMAGES. GERMANY/US: KNOLL, MYOGEN IN RESEARCH DEAL. GERMANY/US: BAYER, MYRIAD R&D INTO OBESITY
- Abstracts: GERMANY: ATRIX CANCER DRUG BY MEDIGENE. SWITZERLAND: EUROPEAN HEADQUARTERS FOR SUGEN. SWITZERLAND/US: ROCHE, OSI IN CANCER R&D DEAL
- Abstracts: GERMANY: RESEARCH DEAL BY SCHWARZ, SCHERING. GERMANY: SCHWARZ PHARMA IN R&D DEAL. GERMANY: MADAUS, SCHWARZ PHARMA IN UROLOGY JV